Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05958901
Recruiting Observational

Pulmonary Hypertension Observational Study

NCT05958901 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Phase
Observational
Started
2023-07-12
Last updated
2023-07-25

Condition(s) studied

Pulmonary Hypertension

Investigational drug(s) / intervention(s)

pulmonary hypertension

pulmonary hypertension: The final outcome observed was a diagnosis of pulmonary hypertension.

Study summary

The purpose of this study is to establish the large PH cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices.

Eligibility

Sex
ALL
Min age
20 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * PH group: When the mean pulmonary artery pressure is greater than 25mmHg at rest or greater than 30mmHg during exercise. * Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years. Exclusion Criteria: * Acute exacerbation in the past 3 months Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc. * Serious uncontrolled diseases thoracic or abdominal surgery in the last 3 months. * Eye surgery in the last three months. * Retinal detachment myocardial infarction in the last 3 months. * Admission to hospital for any cardiac condition in the last month. * Heart rate over 120 beats per minute. * Antibacterial chemotherapy for tuberculosis pregnant or breast feeding.

Primary outcome measure(s)

  • mean pulmonary arterial pressure — 12 months
    For an adult at sea level, when the mean pulmonary arterial pressure is greater than 25 mmHg at rest or greater than 30mmHg during exercise.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong Recruiting

More The First Affiliated Hospital of Guangzhou Medical University trials in China

Cross-Regional Unmanned Aircraft Transport of Donor Lungs Starting soon
Multimodal AI-Guided Recovery Management After Lung Cancer Surgery Recruiting
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Starting soon
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. Recruiting
AI in Respiratory Disease Prevention, Diagnosis, and Triage Enrolling by invitation

Other trials for the same condition

Clinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure Active, not recruiting
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study Recruiting
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension Recruiting
Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study Recruiting
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05958901 on ClinicalTrials.gov ↗ ← All trials in China